Table 2 Cytokines and chemokines expression in overweight volunteers after 180 days of supplementation.
Group | NSupple | NSupple_Silybum | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
T0 | T180 | p | T0 | T180 | p | |||||
(pg/mL) | Mean ± SD | Min–Max | Mean ± SD | Min–Max | Mean ± SD | Min–Max | Mean ± SD | Min–Max | ||
IL-1β | 2.48 ± 0.72 | 1.01–5.69 | 1.88 ± 0.53 | 0.01–4.28 | - | 2.42 ± 1.05 | 1.40–3.65 | 2.24 ± 0.63 | 1.26–2.67 | - |
IL-4 | 4.72 ± 1.02 | 0.01–14.01 | 6.06 ± 1.26 | 0.01–18.42 | 0.017 | 5.71 ± 1.44 | 0.01 -14.72 | 7.47 ± 2.37 | 1.16–26.79 | 0.032 |
IL-6 | 1.17 ± 0.13 | 1.01–1.47 | 1.36 ± 0.31 | 1.01–2.14 | 0.022 | 1.39 ± 0.18 | 1.14–1.55 | 1.14 ± 0.12 | 1.01–1.32 | 0.016 |
IL-10 | 2.72 ± 0.16 | 1.33–4.19 | 2.81 ± 0.20 | 2.04–5.16 | - | 2.54 ± 0.95 | 1.52–5.12 | 2.35 ± 0.38 | 1.61–2.91 | - |
IL-12p70 | 6.80 ± 0.52 | 2.93–13.51 | 8.72 ± 0.58 | 3.39–13.58 | 0.002 | 8.63 ± 3.19 | 4.98–17.32 | 8.87 ± 2.45 | 4.44–14.60 | - |
TNF-α | 1.85 ± 0.28 | 1.32–2.42 | 1.85 ± 0.22 | 1.56–2.30 | - | 2.49 ± 1.12 | 1.80–5.92 | 2.10 ± 0.99 | 1.27–5.15 | 0.001 |
IFN-γ | 3.44 ± 1.32 | 1.11–8.54 | 1.53 ± 0.72 | 0.01–4.62 | 0.031 | 7.88 ± 3.27 | 1.31–27.58 | 4.63 ± 2.31 | 0.01–14.95 | 0.027 |
CXCL10/IP-10 | 4.68 ± 0.68 | 1.85–12.30 | 7.09 ± 1.61 | 2.28–30.85 | 0.030 | 4.02 ± 1.66 | 1.95–6.73 | 4.18 ± 0.96 | 2.71 ± 5.74 | - |
CCL5/RANTES | 42.62 ± 6.33 | 8.58–97.52 | 29.84 ± 4.51 | 0.01–69.29 | 0.050 | 36.5 ± 6.92 | 10.02–79.19 | 23.36 ± 2.39 | 12.43–36.04 | 0.029 |
CXCL9/MIG | 133.2 ± 27.03 | 20.20–307.4 | 87.75 ± 15.25 | 26.79–197.1 | 0.037 | 136.5 ± 87.52 | 10.34–296.3 | 91.22 ± 60.66 | 18.79–206.3 | 0.047 |
CXCL8/IL-8 | 67.74 ± 8.85 | 18.14 -166.3 | 70.89 ± 7.55 | 27.54–156.7 | - | 65.28 ± 26.92 | 21.16–122.7 | 71.37 ± 24.66 | 24.48–106.5 | - |
IL-6/IL-10 ratio | 0.45 ± 0.15 | 0.22–0.87 | 0.34 ± 0.21 | 0.01–0.60 | 0.028 | 0.58 ± 0.15 | 0.40–0.80 | 0.45 ± 0.12 | 0.27–0.61 | 0.006 |
TNF-α/IL-10 ratio | 0.68 ± 0.05 | 0.51–0.97 | 0.82 ± 0.10 | 0.11–1.35 | - | 0.93 ± 0.38 | 0.46–1.75 | 0.77 ± 0.18 | 0.43–1.15 | - |